BioPharma Credit PLC
BPCP.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £124,457 | £135,737 | £184,245 | £87,969 |
| % Growth | -8.3% | -26.3% | 109.4% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £124,457 | £135,737 | £184,245 | £87,969 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £1,969 | £1,861 | £1,698 | £2,857 |
| SG&A Expenses | £2,149 | £2,036 | £1,898 | £3,057 |
| Sales & Mktg Exp. | £180 | £175 | £200 | £200 |
| Other Operating Expenses | £130 | £25,243 | £36 | -£47 |
| Operating Expenses | £2,279 | £27,279 | £1,934 | £3,010 |
| Operating Income | £122,178 | £108,458 | £182,311 | £84,959 |
| % Margin | 98.2% | 79.9% | 99% | 96.6% |
| Other Income/Exp. Net | £0 | -£8 | £0 | £29 |
| Pre-Tax Income | £122,178 | £108,450 | £182,311 | £84,959 |
| Tax Expense | £0 | £0 | £0 | £0 |
| Net Income | £122,178 | £108,450 | £182,311 | £84,959 |
| % Margin | 98.2% | 79.9% | 99% | 96.6% |
| EPS | 0.1 | 0.083 | 0.13 | 0.062 |
| % Growth | 20.8% | -36.3% | 110.4% | – |
| EPS Diluted | 0.1 | 0.083 | 0.13 | 0.062 |
| Weighted Avg Shares Out | 1,222,360 | 1,309,419 | 1,363,999 | 1,373,872 |
| Weighted Avg Shares Out Dil | 1,222,360 | 1,309,410 | 1,363,999 | 1,373,872 |
| Supplemental Information | – | – | – | – |
| Interest Income | £1,490 | £4,324 | £1,145 | £3,131 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | -£122,180 | -£108,457 | -£182,340 | -£84,977 |
| EBITDA | £122,178 | £0 | £0 | £0 |
| % Margin | 98.2% | 0% | 0% | 0% |